New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2013
04:55 EDTALKS, ALKS, ANGO, ANGO, SNSS, SNSS, VHS, VHS, IART, IART, OCR, OCR, BKD, BKD, BAX, BAX, ARIA, ARIARBC Capital to host a conference
Healthcare Conference is being held in New York on February 26-27.
News For ALKS;ANGO;SNSS;VHS;IART;OCR;BKD;BAX;ARIA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 22, 2015
15:40 EDTOCROmnicare calls active on working with advisers on potential sale report
Subscribe for More Information
15:34 EDTOCROmnicare working with advisers on potential sale, Bloomberg says
Subscribe for More Information
15:33 EDTOCROmnicare spikes on potential sale report
Shares were last up 7% to $87.04, off the session high at $89.76 which is now resistance. Support is at $83.98.
15:27 EDTOCROmnicare jumps 9.5% to $88.76 after Bloomberg says sale being explored
Subscribe for More Information
15:26 EDTOCROmnicare exploring potential sale, Bloomberg reports
08:49 EDTBAXCTI BioPharma, Baxter to announce Phase 3 pacritinib data at ASCO late-breaker
CTI BioPharma (CTIC) and Baxter (BAX) announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis will be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology, or ASCO, meeting, to be held May 29-June 2 in Chicago. These data have also been selected as part of this year's official ASCO press briefing – titled "Targeted Therapy" – to be held on Saturday, May 30, at 8:00 am CT, the companies said.
07:38 EDTARIAARIAD issued U.S. patent on brigatinib
Subscribe for More Information
07:11 EDTANGOCardiovascular & Interventional Radiological Society of Europe holds conference
Subscribe for More Information
April 21, 2015
14:30 EDTARIAARIAD could be worth double current value to strategic buyer, BBJ BioFlash says
Subscribe for More Information
09:09 EDTBAXJPMorgan medical tech & devices analyst holds analyst/industry conference call
Subscribe for More Information
07:36 EDTARIAARIAD anounces results of preclinical studies on Brigatinib at AACR meeting
ARIAD Pharmaceuticals announced the results of a series of preclinical studies on its investigational tyrosine kinase inhibitor, brigatinib at the American Association for Cancer Research Annual Meeting 2015. Brigatinib is in development for the treatment of patients with anaplastic lymphoma kinase positive metastatic non-small cell lung cancer, who are resistant to crizotinib. An oral presentation describes, for the first time, the design and chemical structure of brigatinib, discovered using ARIAD’s structure-based drug design platform. With the goal of designing a selective ALK inhibitor with broad-based activity against crizotinib-resistant mutants, ARIAD scientists advanced a series of novel compounds culminating in the identification of brigatinib. Brigatinib incorporates unique chemical-design features, including the distinctive use of a recognition element that confers favorable pharmacologic properties. Brigatinib has at least 10-fold greater potency than crizotinib against ALK+ NSCLC cell lines and was broadly active against clinically relevant crizotinib-resistant mutants in preclinical models. A poster presentation shows that brigatinib, at clinically achievable concentrations, has potent anti-tumor activity against a panel of 17 distinct ALK mutants known to confer resistance to other ALK inhibitors. In a separate study designed to model the occurrence of brain metastases in ALK+ lung cancer patients, brigatinib significantly reduced the tumor burden in mice with ALK+ brain tumors compared to the tumors in mice treated with crizotinib. Survival of brigatinib-treated mice was also markedly enhanced compared to the survival duration of crizotinib-treated mice.
April 20, 2015
07:20 EDTARIA, ALKSAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
April 17, 2015
16:36 EDTBAXBaxter says results of Phase III clinical trial of BAX 111 met primary endpoint
Subscribe for More Information
07:36 EDTARIAARIAD presents updated clinical data on Brigatinib
Subscribe for More Information
April 16, 2015
09:03 EDTBAXBaxter submits application to Japan's MHLW for approval of BAX 855
Baxter International (BAX) announced that the company has submitted a new drug application to Japan’s Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII treatment based on ADVATE for patients over 12 years of age with hemophilia A. The submission follows the filing to the United States Food and Drug Administration in late 2014 and is based on positive results from a prospective, global, Phase 3 study of 137 previously treated patients. The results, presented during the European Association for Haemophilia and Allied Disorders meeting in February 2015, demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding episodes and routine prophylaxis for patients who were 12 years or older. Baxter continues to advance a continuation study for patients who completed the pivotal trial and a Phase 3 study among previously treated patients under the age of 12 with severe hemophilia A. Once the pediatric study has been completed, the company expects to file for marketing authorization with the European Medicines Agency in 2016 and intends to seek post-approval label expansion in the U.S. for previously-untreated pediatric patients. BAX 855 is based on ADVATE, a full-length FVIII molecule with more than 12 years of real-world experience. Through a collaboration with Nektar Therapeutics (NKTR), BAX 855 leverages proprietary pegylation technology designed to extend the duration of activity of the protein in the body. This proprietary technology has been used for over 10 years in a number of approved medicines that treat chronic or serious conditions.
April 15, 2015
08:13 EDTBAXCoherus, Baxter announce amendment to etanercept biosimilar agreement
Coherus BioSciences (CHRS) and Baxter International (BAX) announced that they have amended certain financial terms of their collaboration agreement established in August 2013 regarding the development and commercialization of CHS-0214, an etanercept biosimilar product candidate, for Europe, Canada, Brazil, and certain other markets. Under the terms of the amended agreement, certain existing milestones and funding obligations have been revised, and the collaboration has been expanded to include select pre-commercialization activities. In aggregate, the revised milestone payments may exceed the previous Baxter funding obligations by approximately $12M. Additionally, Baxter has agreed to purchase Coherus common stock in a private placement transaction. All other contractual provisions remain materially unchanged.
April 14, 2015
07:38 EDTBAXBaxter removed from the short-term buy list at Deutsche Bank
Subscribe for More Information
07:05 EDTANGONeedham to hold a conference
Subscribe for More Information
April 13, 2015
14:20 EDTARIANHS Scotland accepts ARIAD's Iclusig for use
Subscribe for More Information
09:07 EDTOCROmnicare has a conference call hosted by JPMorgan
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use